Your browser doesn't support javascript.
loading
Prevalence of Headache in Patients With Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of 14,275 Patients.
Islam, Md Asiful; Alam, Sayeda Sadia; Kundu, Shoumik; Hossan, Tareq; Kamal, Mohammad Amjad; Cavestro, Cinzia.
Afiliación
  • Islam MA; Department of Hematology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.
  • Alam SS; Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Bangladesh.
  • Kundu S; Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Bangladesh.
  • Hossan T; Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Bangladesh.
  • Kamal MA; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
  • Cavestro C; West China School of Nursing, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Institutes for Systems Genetics, Sichuan University, Chengdu, China.
Front Neurol ; 11: 562634, 2020.
Article en En | MEDLINE | ID: mdl-33329305
Background: Coronavirus disease 2019 (COVID-19) started to spread globally since December 2019 from Wuhan, China. Headache has been observed as one of the clinical manifestations in COVID-19 patients. We aimed to conduct a comprehensive systematic review and meta-analysis to estimate the overall pooled prevalence of headache in COVID-19 patients. Methods: PubMed, Scopus, ScienceDirect, and Google Scholar databases were searched to identify studies published between December 2019 and March 2020. Adult (≥18 years) COVID-19 patients were considered eligible. We used random-effects model to estimate the pooled prevalence with 95% confidence intervals (CIs). Quality assessment was done using the Joanna Briggs Institute critical appraisal tools. This study is registered with PROSPERO (CRD42020182529). Results: We identified 2,055 studies, of which 86 studies (n = 14,275, 49.4% female) were included in the meta-analysis. Overall, the pooled prevalence of headache in COVID-19 patients was 10.1% [95% CI: 8.76-11.49]. There was no significant difference of headache prevalence in severe or critical vs. non-severe (RR: 1.05, p = 0.78), survived (recovered or discharged) vs. non-survived (RR: 1.36, p = 0.23), and ICU vs. non-ICU (RR: 1.06, p = 0.87) COVID-19 patients. We detected 64.0, 34.9, and 1.1% of the included studies as high, moderate, and low quality, respectively. Conclusions: From the first 4-month data of the outbreak, headache was detected in 10.1% of the adult COVID-19 patients.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prevalence_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Front Neurol Año: 2020 Tipo del documento: Article País de afiliación: Malasia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prevalence_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Front Neurol Año: 2020 Tipo del documento: Article País de afiliación: Malasia Pais de publicación: Suiza